

Amendments to the Specification

Please replace paragraph [0065] with the following amended paragraph:

The term a "condition that modulates integrins or integrin receptors" refers to any condition that might accomplish integrin or integrin receptor modulation. In addition to the compounds referred to in the earlier previous paragraph, additional examples of modulatory compounds that ~~may be used with modulatory compounds~~ include amyloid beta peptide ~~and mimetics thereof~~, oxidative free radicals (OH, O₂, etc), lysosomal enzyme inhibitors (chloroquine, N-CBZ-L-phenylalanyl-L-alanine-diazomethylketone, NCBZ-L-phenylalanyl-L-phenyl-alanine-diazomethylketon, β-amyloid, and mimetics thereof, etc.), or inflammatory factors (TGF β , IL-1 β , LPS, *etc.*). These compounds can be used individually or in a cocktail containing a combination of more than one compound or in combination with the above modulatory compounds.